Arrowhead Pharmaceuticals Inc (ARWR)
Return on equity (ROE)
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -599,493 | -538,636 | -470,789 | -296,814 | -205,275 | -181,107 | -150,207 | -154,516 | -176,063 | -153,926 | -111,804 | -182,988 | -140,848 | -125,907 | -109,594 | -102,612 | -84,553 | -24,415 | 9,532 | 53,265 |
| Total stockholders’ equity | US$ in thousands | 185,444 | 330,547 | 483,794 | 160,407 | 271,343 | 364,830 | 446,772 | 377,039 | 398,520 | 453,927 | 452,266 | 372,560 | 408,822 | 436,890 | 445,549 | 454,472 | 461,779 | 493,140 | 494,119 | 500,084 |
| ROE | -323.27% | -162.95% | -97.31% | -185.04% | -75.65% | -49.64% | -33.62% | -40.98% | -44.18% | -33.91% | -24.72% | -49.12% | -34.45% | -28.82% | -24.60% | -22.58% | -18.31% | -4.95% | 1.93% | 10.65% |
September 30, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-599,493K ÷ $185,444K
= -323.27%
Arrowhead Pharmaceuticals Inc's return on equity (ROE) has shown a significant fluctuation over the past several quarters, indicating inconsistent performance in generating profits relative to shareholders' equity. The ROE has been negative for most periods, with the latest figure standing at -323.27% as of September 30, 2024. This signifies that the company incurred a substantial loss relative to its equity in that period.
The trend suggests that Arrowhead Pharmaceuticals Inc has been struggling to effectively utilize shareholders' equity to generate returns during these periods. The company experienced a particularly challenging performance in the most recent quarters, with ROE deteriorating significantly. Investors and analysts may view the persistently negative ROE as a cause for concern regarding the company's profitability and operational efficiency.
It would be advisable for stakeholders to closely monitor Arrowhead Pharmaceuticals Inc's financial performance and assess the factors contributing to the fluctuating ROE in order to gain insights into the company's ability to deliver value to shareholders in the future.
Peer comparison
Sep 30, 2024